Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Th2 cytokines correlated with serum vitamin D levels in CR.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Laboratory / cell research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
We focus here on dissection of in vitro and in vivo IFN responses in MS.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
IFN-β therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses
Study design awaiting verification · PLOS One · 2025
Original publication title
IFN-β therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses
© 2025 Li et al
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Dysfunctional regulatory T cells and subnormal responses to interferon-β disrupt the immune system in multiple sclerosis. We probed dysregulated type I IFN pathways in vitro and in vivo IFN-β to induce transcription factors, cytokines, and neurotrophic factors.
Source: IntroductionAbstract: What methods does the paper describe?
36 MS-relevant serum proteins curated to be relevant to MS were detected with multiplex and IFN activity assays plus western blots of mononuclear cells from 15 partial responders (PR) to IFN-β therapy with exacerbations over five years of treatment, and 12 clinical responders (CR) without exacerbations. Response was measured 0, 4, and 24 hours after injection of 16 million units (MU) of IFN-β (double-dose) and 8 MU (standard dose), in clinically stable PR and CR, and 16 MU IFN-β in paired PR during exacerbations, an IFN-resistant state.
IFN-β effects after therapy washout were compared to 15 therapy-naïve stable and 13 active RRMS and 18 healthy controls (HC).
Source: MethodsAbstract: Results
IFN-β injection corrected subnormal levels of p-S-STAT1 transcription factor and induced antiviral MxA and type I IFNs. IFN-β induced anti-inflammatory IL-4, IL-10, IL-12p40, and TNFRII more strongly in stable PR than CR. Th2 cytokines correlated with serum vitamin D levels in CR. During exacerbations, IFN-β injections induced Th1, Th2, and neurotropic proteins. After therapy washout, serum IFN-α/β and pro-inflammatory IL-12p70 levels were lower in stable CR than in PR. In therapy-naïve MS, Th1, Th2, and neurotrophic protein levels were surprisingly subnormal and poorly intercorrelated.
Long-term IFN-β therapy elevated serum proteins and brought them to a balanced positively-correlated state, echoing HC.
Source: ResultsAbstract: Conclusions
IFN-β corrects low serum type I IFN levels, enhances responses to subsequent IFN exposure, induces immunoregulatory and neuroprotective proteins, and balances dysregulated and subnormal serum cytokine levels. Low serum IFN and IFN-β-induced proteins link to better long-term response to IFN-β therapy. Correction of immune disruption suggests new mechanisms for immunopathology and therapy.
Source: ConclusionsAuthors’ abstract
Introduction
Dysfunctional regulatory T cells and subnormal responses to interferon-β disrupt the immune system in multiple sclerosis. We probed dysregulated type I IFN pathways in vitro and in vivo IFN-β to induce transcription factors, cytokines, and neurotrophic factors.
Methods
36 MS-relevant serum proteins curated to be relevant to MS were detected with multiplex and IFN activity assays plus western blots of mononuclear cells from 15 partial responders (PR) to IFN-β therapy with exacerbations over five years of treatment, and 12 clinical responders (CR) without exacerbations. Response was measured 0, 4, and 24 hours after injection of 16 million units (MU) of IFN-β (double-dose) and 8 MU (standard dose), in clinically stable PR and CR, and 16 MU IFN-β in paired PR during exacerbations, an IFN-resistant state.
IFN-β effects after therapy washout were compared to 15 therapy-naïve stable and 13 active RRMS and 18 healthy controls (HC).
Results
IFN-β injection corrected subnormal levels of p-S-STAT1 transcription factor and induced antiviral MxA and type I IFNs. IFN-β induced anti-inflammatory IL-4, IL-10, IL-12p40, and TNFRII more strongly in stable PR than CR. Th2 cytokines correlated with serum vitamin D levels in CR. During exacerbations, IFN-β injections induced Th1, Th2, and neurotropic proteins. After therapy washout, serum IFN-α/β and pro-inflammatory IL-12p70 levels were lower in stable CR than in PR. In therapy-naïve MS, Th1, Th2, and neurotrophic protein levels were surprisingly subnormal and poorly intercorrelated.
Long-term IFN-β therapy elevated serum proteins and brought them to a balanced positively-correlated state, echoing HC.
Conclusions
IFN-β corrects low serum type I IFN levels, enhances responses to subsequent IFN exposure, induces immunoregulatory and neuroprotective proteins, and balances dysregulated and subnormal serum cytokine levels. Low serum IFN and IFN-β-induced proteins link to better long-term response to IFN-β therapy. Correction of immune disruption suggests new mechanisms for immunopathology and therapy.
Publication and source details
Original title: IFN-β therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses
Lei Li; Maya Olcer; Zhe Wang; Yaerin Song; Jeffrey Ke; Xuan Feng; Anthony T. Reder
PLOS One · 2025
Competing Interests: The authors have declared that no competing interests exist.
☯ Co first authors.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:06:25.084277+00:00
DOI: 10.1371/journal.pone.0330867 · PMC12449033